Axogen earnings release, July 29, 2026
Axogen, Inc. Reports Second Quarter 2026 Financial Results
Raises Full Year Revenue Guidance to at Least 24% Growth or $279 million
ALACHUA and TAMPA, FL – July 29, 2026 – Axogen, Inc. (NASDAQ: AXGN), a global leader in developing and marketing innovative surgical solutions for the restoration of peripheral nerve function, today reported financial results and business highlights for the second quarter ended June 30, 2026.
Second Quarter Financial Results
• Revenue was $69.7 million, an increase of 23.1% compared with $56.7 million in the second quarter of 2025.
• Gross margin was 72.7% compared to 74.2% in the second quarter of 2025. Gross margin performance was driven by changes in product mix caused primarily by accelerating year over year Breast growth greater than 50%.
• Net loss was $1.5 million, or $0.03 per share, compared to a Net income of $0.6 million, or $0.01 per share for the second quarter of 2025.
• Adjusted net income was $7.3 million, or $0.12 per share, as compared to $5.7 million, or $0.12 per share for the second quarter of 2025.
• Adjusted EBITDA was $8.4 million, compared to $9.3 million for the second quarter of 2025.
• Cash and cash equivalents, restricted cash, and investments as of June 30, 2026 was $113.4 million, as compared to $103.6 million as of March 31, 2026, an increase of $9.8 million.
“We are pleased with our second-quarter revenue performance and the progress we’re making across each of Axogen’s strategic plan priorities,” said Michael Dale, President and CEO of Axogen, Inc. “Our strong growth across all our target markets, continues to reinforce the relevance of our market development strategies and the strength of our commercial execution. We remain well positioned to achieve our revenue guidance and continue advancing our strategic objectives for 2026.”
Summary of Business Highlights
• Year-to-date revenue growth through the second quarter of 2026 was broad-based across Extremities, Oral Maxillofacial & Head and Neck, and Breast, driven by 20% plus year-over-year account productivity, expanding sales force coverage, and improving commercial insurance coverage and payment.
• Publication of REPOSE, a prospective, randomized clinical study evaluating Axoguard Nerve Cap for symptomatic neuroma management, providing Level 1 evidence supporting nerve end protection and demonstrating favorable outcomes in pain burden, medication utilization, and recovery-related measures.
• Initiated Nerve-RESTORE, a prospective, randomized, assessor-blinded study comparing Avance Nerve Graft to sural nerve autograft in mixed and motor nerve reconstruction, designed to generate Level 1 evidence supporting broader adoption of nerve repair globally.
• Acquired a minority ownership stake in Trace Biosciences, including a limited right of first refusal, to support development of its nerve-specific imaging technology.
2026 Financial Guidance
For 2026, we expect full-year revenue growth to be at least 24%, or revenue of at least $279 million, gross margin to be at least 73%, and positive free cash flow for the full-year.
Conference Call
The Company will host a conference call and webcast for the investment community today at 8:00 a.m. ET. Investors interested in participating in the conference call by phone may do so by dialing toll free at (877) 407-0993 or use the direct dial-in number at (201) 689-8795. Those interested in listening to the conference call live via the internet may do so by visiting the Investors page of the Company’s website at www.axogeninc.com and clicking on the webcast link.
Following the conference call, a replay will be available in the Investors section of the Company’s website at www.axogeninc.com under Investors.
About Axogen
Axogen (AXGN) is the leading company focused specifically on the science, development and commercialization of technologies for peripheral nerve regeneration and repair. Axogen employees are passionate about providing the opportunity to restore nerve function and quality of life for patients with peripheral nerve injuries by providing innovative, clinically proven and economically effective repair solutions for surgeons and healthcare providers. Peripheral nerves provide the pathways for both motor and sensory signals throughout the body. Every day people suffer traumatic injuries or undergo surgical procedures that impact the function of their peripheral nerves. Physical damage to a peripheral nerve or the inability to properly reconnect peripheral nerves can result in the loss of muscle or organ function, the loss of sensory feeling, or the initiation of pain.
Axogen’s product portfolio includes Avance®
(acellular nerve allograft-arwx), Avance®
Nerve Graft, Axoguard Nerve Connector®, Axoguard Nerve Protector®, Axoguard HA+ Nerve Protector™, Axoguard Nerve Cap®, and Avive+ Soft Tissue Matrix™.
For more information, visit www.axogeninc.com.
Financial statements
Income Statement
Three Months Ended — (in thousands, except share and per share amounts)
| Three Months Ended – June 30, 2026 | Three Months Ended – June 30, 2025 | Six Months Ended – June 30, 2026 | Six Months Ended – June 30, 2025 | ||
|---|---|---|---|---|---|
| Revenues | 69,731 | 56,662 | 131,188 | 105,222 | |
| Cost of goods sold | 19,057 | 14,644 | 34,325 | 28,271 | |
| Gross profit | 50,674 | 42,018 | 96,863 | 76,951 | |
| Costs and expenses: | Sales and marketing | 30,827 | 23,804 | 59,460 | 44,849 |
| Costs and expenses: | Research and development | 8,589 | 6,853 | 16,106 | 12,944 |
| Costs and expenses: | General and administrative | 13,414 | 9,689 | 26,285 | 19,147 |
| Costs and expenses: | Total costs and expenses | 52,830 | 40,346 | 101,851 | 76,940 |
| Costs and expenses: | (Loss) income from operations | -2,156 | 1,672 | -4,988 | 11 |
| Other income (expense): | Investment income | 786 | 225 | 1,554 | 497 |
| Other income (expense): | Interest expense | -1 | -1,977 | -695 | -4,227 |
| Other income (expense): | Loss on extinguishment of debt | -16,849 | |||
| Other income (expense): | Change in fair value of debt derivative liabilities | 480 | 322 | ||
| Other income (expense): | Other (expense) income, net | -145 | 179 | -122 | 142 |
| Other income (expense): | Total other income (expense), net | 640 | -1,093 | -16,112 | -3,266 |
| Other income (expense): | Net (loss) income | -1,516 | 579 | -21,100 | -3,255 |
| Other income (expense): | Weighted average common shares outstanding — basic | 53,339,258 | 46,063,092 | 52,562,976 | 45,605,419 |
| Other income (expense): | Weighted average common shares outstanding — diluted | 53,339,258 | 47,980,830 | 52,562,976 | 45,605,419 |
| Other income (expense): | Net (loss) income per common share — basic | -0.03 | 0.01 | -0.4 | -0.07 |
| Other income (expense): | Net (loss) income per common share — diluted | -0.03 | 0.01 | -0.4 | -0.07 |
Income Statement
Common Stock — (in thousands, except share amounts)
| Common Stock – Shares | Common Stock – Amount | Additional Paid-in Capital | Accumulated Deficit | Total Shareholders' Equity | ||
|---|---|---|---|---|---|---|
| Three Months Ended June 30, 2026 | Balance at March 31, 2026 | 53,153,471 | 532 | 570,823 | -326,547 | 244,808 |
| Three Months Ended June 30, 2026 | Net loss | -1,516 | -1,516 | |||
| Three Months Ended June 30, 2026 | Stock-based compensation | 8,766 | 8,766 | |||
| Three Months Ended June 30, 2026 | Issuance of restricted and performance stock units, net of shares withheld for withholding taxes | 134,892 | 1 | -498 | -497 | |
| Three Months Ended June 30, 2026 | Exercise of stock options and employee stock purchases under the ESPP | 367,930 | 4 | 4,692 | 4,696 | |
| Three Months Ended June 30, 2026 | Balance at June 30, 2026 | 53,656,293 | 537 | 583,783 | -328,063 | 256,257 |
| Six Months Ended June 30, 2026 | Balance at December 31, 2025 | 47,199,797 | 472 | 435,338 | -306,963 | 128,847 |
| Six Months Ended June 30, 2026 | Net loss | -21,100 | -21,100 | |||
| Six Months Ended June 30, 2026 | Issuance of common shares | 4,600,000 | 46 | 133,206 | 133,252 | |
| Six Months Ended June 30, 2026 | Stock-based compensation | 15,609 | 15,609 | |||
| Six Months Ended June 30, 2026 | Issuance of restricted and performance stock units, net of shares withheld for withholding taxes | 1,120,688 | 11 | -9,284 | -9,273 | |
| Six Months Ended June 30, 2026 | Exercise of stock options and employee stock purchases under the ESPP | 735,808 | 8 | 8,914 | 8,922 | |
| Six Months Ended June 30, 2026 | Balance at June 30, 2026 | 53,656,293 | 537 | 583,783 | -328,063 | 256,257 |
| Three Months Ended June 30, 2025 | Balance at December 31, 2024 | 45,512,623 | 455 | 400,004 | -295,094 | 105,365 |
| Three Months Ended June 30, 2025 | Net income | 579 | 579 | |||
| Three Months Ended June 30, 2025 | Stock-based compensation | 5,168 | 5,168 | |||
| Three Months Ended June 30, 2025 | Issuance of restricted and performance stock units | 113,923 | 1 | -1 | ||
| Three Months Ended June 30, 2025 | Exercise of stock options and employee stock purchases under the ESPP | 138,744 | 1 | 1,163 | 1,164 | |
| Three Months Ended June 30, 2025 | Balance at June 30, 2025 | 45,765,290 | 457 | 406,334 | -294,515 | 112,276 |
| Six Months Ended June 30, 2025 | Balance at December 31, 2024 | 44,148,836 | 441 | 394,726 | -291,260 | 103,907 |
| Six Months Ended June 30, 2025 | Net loss | -3,255 | -3,255 | |||
| Six Months Ended June 30, 2025 | Stock-based compensation | 8,077 | 8,077 | |||
| Six Months Ended June 30, 2025 | Issuance of restricted and performance stock units | 1,219,137 | 12 | -12 | ||
| Six Months Ended June 30, 2025 | Exercise of stock options and employee stock purchases under the ESPP | 397,317 | 4 | 3,543 | 3,547 | |
| Six Months Ended June 30, 2025 | Balance at June 30, 2025 | 45,765,290 | 457 | 406,334 | -294,515 | 112,276 |
Income Statement
EBITDA & Adjusted EBITDA — (in thousands, except share and per share amounts)
| Three Months Ended – June 30, 2026 | Three Months Ended – June 30, 2025 | Six Months Ended – June 30, 2026 | Six Months Ended – June 30, 2025 | |
|---|---|---|---|---|
| Net (loss) income | -1,516 | 579 | -21,100 | -3,255 |
| Depreciation and amortization expense | 1,717 | 1,723 | 3,422 | 3,518 |
| Investment income | -786 | -225 | -1,554 | -497 |
| Income tax expense | 221 | 37 | 188 | 66 |
| Interest expense | 1 | 1,977 | 695 | 4,227 |
| EBITDA - non-GAAP | -363 | 4,091 | -18,349 | 4,059 |
| EBITDA margin - non-GAAP | -0.5 | 7.2 | -14 | 3.9 |
| Non-cash stock-based compensation expense | 8,766 | 5,168 | 15,609 | 8,077 |
| Loss on extinguishment of debt | 16,849 | |||
| Adjusted EBITDA - non-GAAP | 8,403 | 9,259 | 14,109 | 12,136 |
| Adjusted EBITDA margin - non-GAAP | 12.1 | 16.3 | 10.8 | 11.5 |
Income Statement
Adjusted Net Income — (in thousands, except share and per share amounts)
| GAAP Results | Non-cash Stock-based Compensation Expense | Adjusted Results | ||||
|---|---|---|---|---|---|---|
| Revenues | GAAP Results | 56,662 | Non-cash Stock-based Compensation Expense | Adjusted Results | 56,662 | |
| Cost of goods sold | 14,644 | -710 | 13,934 | |||
| Gross profit | 42,018 | 710 | 42,728 | |||
| Costs and expenses: | Sales and marketing | 23,804 | -1,314 | 22,490 | ||
| Costs and expenses: | Research and development | 6,853 | -1,029 | 5,824 | ||
| Costs and expenses: | General and administrative | 9,689 | -2,115 | 7,574 | ||
| Costs and expenses: | Total costs and expenses | 40,346 | -4,458 | 35,888 | ||
| Costs and expenses: | Income from operations | 1,672 | 5,168 | 6,840 | ||
| Other income (expense): | Investment income | 225 | 225 | |||
| Other income (expense): | Interest expense | -1,977 | -1,977 | |||
| Other income (expense): | Change in fair value of debt derivative liabilities | 480 | 480 | |||
| Other income (expense): | Other income, net | 179 | 179 | |||
| Other income (expense): | Total other expense, net | -1,093 | -1,093 | |||
| Other income (expense): | Net income | 579 | 5,168 | 5,747 | ||
| Other income (expense): | Weighted average common shares outstanding - diluted | 47,980,830 | 47,980,830 | 47,980,830 | ||
| Other income (expense): | Net income per common share - diluted | 0.01 | 0.11 | 0.12 |
Income Statement
Adjusted Net Income — (in thousands, except share and per share amounts)
| Six Months Ended June 30, 2026 – GAAP Results | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2026 – Non-cash Stock-based Compensation Expense | Six Months Ended June 30, 2026 – Loss on Extinguishment of Debt | Six Months Ended June 30, 2026 – Dilutive Shares Impact(1) | Six Months Ended June 30, 2026 – Adjusted Results | |||
|---|---|---|---|---|---|---|---|---|
| Revenues | GAAP Results | 131,188 | Non-cash Stock-based Compensation Expense | Loss on Extinguishment of Debt | Adjusted Results | 131,188 | ||
| Cost of goods sold | 34,325 | -2,129 | 32,196 | |||||
| Gross profit | 96,863 | 2,129 | 98,992 | |||||
| Costs and expenses: | Sales and marketing | 59,460 | -3,561 | 55,899 | ||||
| Costs and expenses: | Research and development | 16,106 | -3,214 | 12,892 | ||||
| Costs and expenses: | General and administrative | 26,285 | -6,705 | 19,580 | ||||
| Costs and expenses: | Total costs and expenses | 101,851 | -13,480 | 88,371 | ||||
| Costs and expenses: | (Loss) income from operations | -4,988 | 15,609 | 10,621 | ||||
| Other income (expense): | Investment income | 1,554 | 1,554 | |||||
| Other income (expense): | Interest expense | -695 | -695 | |||||
| Other income (expense): | Loss on extinguishment of debt | -16,849 | 16,849 | |||||
| Other income (expense): | Other expense, net | -122 | -122 | |||||
| Other income (expense): | Total other (expense) income, net | -16,112 | 16,849 | 737 | ||||
| Other income (expense): | Net (loss) income | -21,100 | 15,609 | 16,849 | 11,358 | |||
| Other income (expense): | Weighted average common shares outstanding - diluted | 52,562,976 | 52,562,976 | 52,562,976 | 5,966,877 | 58,529,853 | ||
| Other income (expense): | Net (loss) income per common share - diluted | -0.4 | 0.3 | 0.32 | -0.02 | 0.19 |
Income Statement
Adjusted Net Income — (in thousands, except share and per share amounts)
| GAAP Results | Non-cash Stock-based Compensation Expense | Dilutive Shares Impact(1) | Adjusted Results | ||||
|---|---|---|---|---|---|---|---|
| Revenues | GAAP Results | 105,222 | Non-cash Stock-based Compensation Expense | Adjusted Results | 105,222 | ||
| Cost of goods sold | 28,271 | -700 | 27,571 | ||||
| Gross profit | 76,951 | 700 | 77,651 | ||||
| Costs and expenses: | Sales and marketing | 44,849 | -1,898 | 42,951 | |||
| Costs and expenses: | Research and development | 12,944 | -1,749 | 11,195 | |||
| Costs and expenses: | General and administrative | 19,147 | -3,730 | 15,417 | |||
| Costs and expenses: | Total costs and expenses | 76,940 | -7,377 | 69,563 | |||
| Costs and expenses: | Income from operations | 11 | 8,077 | 8,088 | |||
| Other income (expense): | Investment income | 497 | 497 | ||||
| Other income (expense): | Interest expense | -4,227 | -4,227 | ||||
| Other income (expense): | Change in fair value of debt derivative liabilities | 322 | 322 | ||||
| Other income (expense): | Other income, net | 142 | 142 | ||||
| Other income (expense): | Total other expense, net | -3,266 | -3,266 | ||||
| Other income (expense): | Net (loss) income | -3,255 | 8,077 | 4,822 | |||
| Other income (expense): | Weighted average common shares outstanding - diluted | 45,605,419 | 45,605,419 | 2,650,576 | 48,255,995 |
Balance Sheet
(in thousands, except share and per share amounts)
| June 30, 2026 | December 31, 2025 | ||
|---|---|---|---|
| Current assets: | Cash and cash equivalents | 94,572 | 35,548 |
| Current assets: | Restricted cash | 2,000 | 4,000 |
| Current assets: | Investments | 16,840 | 5,980 |
| Current assets: | Accounts receivable, net of allowance for doubtful accounts of $734 and $948, respectively | 34,126 | 26,169 |
| Current assets: | Inventory | 47,313 | 42,373 |
| Current assets: | Prepaid expenses and other assets | 5,525 | 6,352 |
| Current assets: | Total current assets | 200,376 | 120,422 |
| Current assets: | Property and equipment, net | 82,342 | 81,783 |
| Current assets: | Operating lease right-of-use assets | 13,845 | 12,732 |
| Current assets: | Intangible assets, net | 7,571 | 6,750 |
| Current assets: | Other assets | 729 | |
| Current assets: | Total assets | 304,863 | 221,687 |
| Current liabilities: | Accounts payable and accrued expenses | 28,399 | 21,184 |
| Current liabilities: | Current maturities of long-term lease obligations | 1,975 | 2,372 |
| Current liabilities: | Total current liabilities | 30,374 | 23,556 |
| Current liabilities: | Long-term debt, net of debt discount and financing fees | 48,387 | |
| Current liabilities: | Long-term lease obligations | 18,091 | 16,870 |
| Current liabilities: | Debt derivative liabilities | 3,886 | |
| Current liabilities: | Other long-term liabilities | 141 | 141 |
| Current liabilities: | Total liabilities | 48,606 | 92,840 |
| Shareholders’ equity: | Common stock, $0.01 par value per share; 100,000,000 shares authorized; 53,656,293 and 47,199,797 shares issued and outstanding, respectively | 537 | 472 |
| Shareholders’ equity: | Additional paid-in capital | 583,783 | 435,338 |
| Shareholders’ equity: | Accumulated deficit | -328,063 | -306,963 |
| Shareholders’ equity: | Total shareholders’ equity | 256,257 | 128,847 |
| Shareholders’ equity: | Total liabilities and shareholders’ equity | 304,863 | 221,687 |
Cash Flow
Six Months Ended — (in thousands)
| Six Months Ended – June 30, 2026 | Six Months Ended – June 30, 2025 | ||
|---|---|---|---|
| Cash flows from operating activities: | Net loss | -21,100 | -3,255 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Depreciation | 3,211 | 3,385 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Amortization of right-of-use assets | 854 | 184 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Amortization of intangible assets | 212 | 133 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Amortization of debt discount and deferred financing fees | 68 | 442 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | (Recovery of) provision for bad debts | -52 | 386 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Loss on disposal of equipment | 7 | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Change in fair value of debt derivative liabilities | -322 | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Investment gains, net | -110 | -121 |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Loss on extinguishment of debt | 16,849 | |
| Adjustments to reconcile net loss to net cash provided by (used in) operating activities: | Stock-based compensation expense | 15,609 | 8,077 |
| Change in operating assets and liabilities: | Accounts receivable | -7,905 | -4,310 |
| Change in operating assets and liabilities: | Inventory | -4,940 | -3,591 |
| Change in operating assets and liabilities: | Prepaid expenses and other assets | 827 | -81 |
| Change in operating assets and liabilities: | Other assets | -729 | |
| Change in operating assets and liabilities: | Accounts payable and accrued expenses | 7,118 | -5,755 |
| Change in operating assets and liabilities: | Operating lease obligations | -1,130 | -542 |
| Change in operating assets and liabilities: | Cash paid for interest portion of financing lease obligations | -3 | -2 |
| Change in operating assets and liabilities: | Other long-term liabilities | -77 | |
| Change in operating assets and liabilities: | Net cash provided by (used in) operating activities | 8,786 | -5,449 |
| Cash flows from investing activities: | Purchase of property and equipment | -3,682 | -978 |
| Cash flows from investing activities: | Purchase of investments | -18,750 | -7,837 |
| Cash flows from investing activities: | Proceeds from sale of investments | 8,000 | 4,000 |
| Cash flows from investing activities: | Cash payments for intangible assets | -1,032 | -793 |
| Cash flows from investing activities: | Net cash used in investing activities | -15,464 | -5,608 |
| Cash flows from financing activities: | Proceeds from issuance of common stock | 134,044 | |
| Cash flows from financing activities: | Payment of stock issuance costs | -792 | |
| Cash flows from financing activities: | Repayment of long-term debt | -48,585 | |
| Cash flows from financing activities: | Fees paid to lender related to debt extinguishment | -20,498 | |
| Cash flows from financing activities: | Fees paid to third parties related to debt extinguishment | -107 | |
| Cash flows from financing activities: | Payments of employee tax withholding on vested stock awards | -9,273 | |
| Cash flows from financing activities: | Cash paid for debt portion of financing lease obligations | -9 | -8 |
| Cash flows from financing activities: | Proceeds from exercise of stock options and ESPP stock purchases | 8,922 | 3,547 |
| Cash flows from financing activities: | Net cash provided by financing activities | 63,702 | 3,539 |
| Cash flows from financing activities: | Net increase (decrease) in cash and cash equivalents, and restricted cash | 57,024 | -7,518 |
| Cash flows from financing activities: | Cash and cash equivalents, and restricted cash, beginning of period | 39,548 | 33,554 |
Cash Flow
Free Cash Flow
| Six Months Ended June 30, – 2026 | Six Months Ended June 30, – 2025 | |
|---|---|---|
| Net cash provided by (used in) operating activities | 8,786 | -5,449 |
| Purchase of property and equipment | -3,682 | -978 |
| Cash payments for intangible assets | -1,032 | -793 |
| Free cash flow | 4,072 | -7,220 |
Full release
Cautionary Statements Concerning Forward-Looking Statements... (truncated)eks,” “estimates,” “projects,” “forecasts,” “continue,” “may,” “should,” “will,” and variations of such words and similar expressions are intended to identify such forward-looking statements. Actual results or events could differ materially from those described in any forward-looking statements as a result of factors, including, without limitation, disruptions from global supply chain issues, inflation, hospital staffing challenges, product development timelines, regulatory processes, financial performance, surgeon adoption rates, market awareness of our products, the estimated total addressable market, as well as those risk factors described under Part I, Item 1A, “Risk Factors,” in our most recent Annual Report on Form 10-K and other risks and uncertainties that may be detailed from time to time in reports filed by the Company with the SEC. Forward-looking statements are not a guarantee of future performance, and actual results may differ materially from those projected. Forward-looking statements speak only as of the date they are made and, except as required by applicable law, we assume no responsibility to publicly update or revise any forward-looking statements.
About Non-GAAP Financial Measures
To supplement our condensed consolidated financial statements, we use the non-GAAP financial measures of EBITDA, which measures earnings before interest, income taxes, depreciation and amortization, EBITDA margin, and Adjusted EBITDA, which further excludes non-cash stock-based compensation expense and the loss on extinguishment of debt, and Adjusted EBITDA margin. We also use the non-GAAP financial measures of Adjusted Net Income and Adjusted Net Income Per Common Share - diluted which excludes non-cash stock-based compensation expense and the loss on extinguishment of debt from Net (Loss) Income and Net (Loss) Income Per Common Share - diluted. Additionally, we use the non-GAAP financial measure of Free Cash Flow which consists of net cash provided by operating activities, less expenditures for property and equipment, and intangible assets.
These non-GAAP measures are not based on any comprehensive set of accounting rules or principles and should not be considered a substitute for, or superior to, financial measures calculated in accordance with GAAP and may be different from non-GAAP measures used by other companies. In addition, these non-GAAP measures should be read in conjunction with our financial statements prepared in accordance with GAAP. The reconciliations of the non-GAAP measures to the most directly comparable financial measures calculated and presented in accordance with GAAP should be carefully evaluated.
We use these non-GAAP financial measures for financial and operational decision-making and as a means to evaluate period-to-period comparisons. We believe that these non-GAAP financial measures provide meaningful supplemental information regarding our performance and that both management and investors benefit from referring to these non-GAAP financial measures in assessing our performance and when planning, forecasting, and analyzing future periods. We believe these non-GAAP financial measures are useful to investors because (i) they allow for greater transparency with respect to key metrics used by management in its financial and operational decision-making and (ii) they are used by our institutional investors and the analyst community to help them analyze the performance of our business.
Axogen, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
(in thousands, except share and per share amounts)
Axogen, Inc.
Condensed Consolidated Statements of Operations
(unaudited)
(in thousands, except share and per share amounts)
Axogen, Inc.
Condensed Consolidated Statements of Cash Flows
(unaudited)
(in thousands)
Axogen, Inc.
Condensed Consolidated Statements of Changes in Shareholders’ Equity
(unaudited)
(in thousands, except share amounts)
Axogen, Inc.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(unaudited)
(in thousands, except share and per share amounts)
__________
(1)
Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.
Axogen, Inc.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(unaudited)
(in thousands, except share and per share amounts)
Axogen, Inc.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(unaudited)
(in thousands, except share and per share amounts)
__________
(1)
Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.
Axogen, Inc.
Reconciliation of GAAP Financial Measures to Non-GAAP Financial Measures
(unaudited)
(in thousands, except share and per share amounts)
__________
(1)
Due to a GAAP net loss, antidilutive securities are excluded from GAAP diluted weighted average common shares outstanding. However, considering the adjusted net income position, adjusted diluted weighted average common shares outstanding incorporates securities that would have been dilutive for GAAP.